Kaspofungin Viatris

Caspofungin, the active ingredient in Kaspofungin Viatris, is an echinocandin presented as an intravenous solution for intravenous use. It treats serious fungal infections such as invasive candidiasis, esophageal candidiasis and invasive aspergillosis in adult patients and is indicated for patients with compromised immune systems.

GNH USA supplies Kaspofungin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide across multiple regions, with a focus on quality assurance and regulatory compliance for critical care settings.

Caspofungin is an echinocandin antifungal that targets invasive fungal infections.

Invasive candidiasis: effective in treating bloodstream and deep‑tissue Candida infections. Esophageal candidiasis: resolves infection of the esophageal mucosa caused by Candida species. Invasive aspergillosis: used as part of therapy for severe Aspergillus infections in immunocompromised patients.

Caspofungin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Headache: occasional mild headache. - Elevated liver enzymes: mild increase in ALT/AST.

Serious or Rare Side Effects: - Hypersensitivity reactions: including rash, pruritus, or anaphylaxis. - Severe hepatic dysfunction: marked elevation of liver enzymes or jaundice. - Infusion‑related reactions: chest pain, dyspnea, or hypotension.

When prescribing Kaspofungin Viatris, consider the following precautions.

Renal impairment: dose adjustment may be required in patients with reduced kidney function. Hepatic dysfunction: monitor liver function tests during therapy. Concomitant CYP3A4 inhibitors: may increase caspofungin exposure; consider monitoring. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Drug interactions: review concomitant medications for potential interactions. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Caspofungin can interact with several medicines; assess the clinical relevance before co‑administration.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce caspofungin plasma concentrations. - Concurrent use with other echinocandins: increased risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase caspofungin levels; monitor liver function. - Cyclosporine: may increase caspofungin exposure; consider dose adjustment. - Immunosuppressants: monitor for enhanced immunosuppression.